Provided by Tiger Trade Technology Pte. Ltd.

Dyne Therapeutics, Inc.

18.42
-0.7700-4.01%
Post-market: 18.38-0.0397-0.22%17:26 EDT
Volume:4.71M
Turnover:85.90M
Market Cap:3.44B
PE:-5.50
High:19.03
Open:19.03
Low:17.93
Close:19.19
52wk High:27.31
52wk Low:11.92
Shares:186.58M
Float Shares:186.00M
Volume Ratio:0.86
T/O Rate:2.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3486
EPS(LYR):-3.4740
ROE:-81.57%
ROA:-38.96%
PB:4.89
PE(LYR):-5.30

Loading ...

Dyne Therapeutics Q1 EPS USD -0.73 VS. Ibes Estimate USD -0.77

THOMSON REUTERS
·
May 11

Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

GlobeNewswire
·
May 11

Dyne Therapeutics Q1 net loss widens to $120.9 million

Reuters
·
May 11

Dyne Therapeutics director Jason P. Rhodes disposes of common shares worth $1.94 million

Reuters
·
May 07

Dyne Therapeutics director Jason P. Rhodes disposes of shares worth $4.18 million

Reuters
·
May 01

Dyne Therapeutics Director Jason P. Rhodes disposes of $6.76 million in shares

Reuters
·
Apr 28

Dyne to present primate data showing FORCE platform crosses blood-brain barrier

Reuters
·
Apr 28

Dyne director Dirk Kersten reports DYN share sale worth $219,364

Reuters
·
Apr 24

Dyne Therapeutics grants inducement awards to 18 new employees under Nasdaq rule

Reuters
·
Apr 24

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Apr 24

Dyne Therapeutics director Dirk Kersten disposes of USD 6.8 million common shares

Reuters
·
Apr 22

Dyne director Dirk Kersten disposes of $2,021,419 Dyne Therapeutics shares

Reuters
·
Apr 18

Dyne Therapeutics Advances Pivotal DYNE-101 Trial in Myotonic Dystrophy Type 1

TIPRANKS
·
Apr 17

Dyne Therapeutics announces annual shareholder meeting agenda

Reuters
·
Apr 10

Dyne director Brian S. Posner acquires Dyne Therapeutics shares worth $0.03 million

Reuters
·
Apr 02

Dyne to present DELIVER, ACHIEVE trial data at AMCP as it readies US DMD launch

Reuters
·
Apr 01

J.P. Morgan Reaffirms Their Hold Rating on Dyne Therapeutics (DYN)

TIPRANKS
·
Mar 16